Pathogenesis of Chronic Progressive Myelopathy Associated with Human T-cell Lymphotropic Virus Type I
Overview
Authors
Affiliations
Human T-cell lymphotropic virus type I (HTLV-I) induces a chronic demyelinating disease known as HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). While only 0.25% of HTLV-I-infected individuals develop HAM/TSP, the mechanisms responsible for the progression of an HTLV-I carrier state to clinical disease are not clear. In particular, no specific sequence differences have been found between HTLV-I recovered from HAM patients and HTLV-I-infected carriers. Since CD4 T cells are the major reservoir of the virus, at least three hypotheses implicating CD4 T cells directly or indirectly have been proposed: 1) The cytotoxic hypothesis predicts that activated and HTLV-I-infected CD4 T cells migrate to the CNS and infect resident cells. Cytotoxic CD8 T cells may then recognize viral antigens on HTLV-I-infected CNS cells causing a cellularly mediated cytotoxic demyelination. 2) The autoimmune hypothesis predicts that either (a) virally reactive T cells crossreact with a CNS antigen, or (b) random infection of CD4 T cells eventually results in the infection of CNS-autoreactive CD4 T cells that, by virtue of the productive HTLV-I infection, become activated, expand and migrate to the CNS, where they encounter their antigen. This results in a specific immune response and demyelination, as is known to occur in experimental autoimmune encephalomyelitis. 3) The bystander damage hypothesis does not implicate a specific response against CNS cells. Instead this hypothesis suggests that the presence of IFN-gamma-secreting HTLV-I-infected CD4 T cells and their recognition by virally specific CD8 T cells in the CNS induce microglia to secrete cytokines, such as TNF-alpha, which may be toxic for the myelin.
Duan J, Lv A, Guo Z, Liu Q, Tian C, Yang Y J Neuroinflammation. 2024; 21(1):254.
PMID: 39385200 PMC: 11465848. DOI: 10.1186/s12974-024-03243-z.
Harding D, Rosadas C, Tsoti S, Heslegrave A, Stewart M, Kelleher P J Neurovirol. 2022; 28(4-6):473-482.
PMID: 35908019 PMC: 9797460. DOI: 10.1007/s13365-022-01088-x.
Pathogenesis of HTLV-1 infection and progression biomarkers: An overview.
Brites C, Grassi M, Quaresma J, Ishak R, Vallinoto A Braz J Infect Dis. 2021; 25(3):101594.
PMID: 34256025 PMC: 9392164. DOI: 10.1016/j.bjid.2021.101594.
Effect of Pulsed Methylprednisolone on Pain, in Patients with HTLV-1-Associated Myelopathy.
Buell K, Puri A, Demontis M, Short C, Adonis A, Haddow J PLoS One. 2016; 11(4):e0152557.
PMID: 27077747 PMC: 4831674. DOI: 10.1371/journal.pone.0152557.
Gudo E, Silva-Barbosa S, Linhares-Lacerda L, Ribeiro-Alves M, Corte Real S, Bou-Habib D Virol J. 2015; 12:165.
PMID: 26458945 PMC: 4603815. DOI: 10.1186/s12985-015-0398-x.